Unravelling tumour heterogeneity using next-generation imaging: radiomics, radiogenomics, and habitat imaging

Clinical Radiology

Volumn 72, Issue 1, 2017, Pages 3-10

  Sala, E ^a   Mema, E ^a,b   Himoto, Y ^a   Veeraraghavan, H ^a   Brenton, J D ^c   Snyder, A ^a   Weigelt, B ^a   Vargas, H A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^c IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER;

CANCER AGGRESSIVENESS; CANCER DIAGNOSIS; CANCER RESISTANCE; CLINICAL OUTCOME; GENETIC HETEROGENEITY; GENOMICS; HABITAT IMAGING; HUMAN; INTRATUMOR HETEROGENEITY; MALIGNANT NEOPLASM; NEXT GENERATION SEQUENCING; ONCOLOGICAL PARAMETERS; PRIORITY JOURNAL; RADIOGENOMICS; RADIOMICS; REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; DIAGNOSTIC IMAGING; EARLY CANCER DIAGNOSIS; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETICS; GENOTYPE ENVIRONMENT INTERACTION; IMAGE ENHANCEMENT; MOLECULAR IMAGING; NEOPLASM; PERSONALIZED MEDICINE; PROCEDURES;

BIOMARKERS, TUMOR; EARLY DETECTION OF CANCER; GENE-ENVIRONMENT INTERACTION; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; GENOMICS; HUMANS; IMAGE ENHANCEMENT; MOLECULAR IMAGING; NEOPLASMS; PRECISION MEDICINE;

EID: 85002169355     PISSN: 00099260     EISSN: 1365229X     Source Type: Journal    
DOI: 10.1016/j.crad.2016.09.013     Document Type: Review

References (56)

1. 1 de Bruin, E.C., McGranahan, N., Mitter, R., et al. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science (New York, NY) 346:6206 (2014), 251–256.
2. 2 Yates, L.R., Gerstung, M., Knappskog, S., et al. Subclonal diversification of primary breast cancer revealed by multiregion sequencing. Nat Med 21:7 (2015), 751–759.
3. 3 Schwarz, R.F., Ng, C.K., Cooke, S.L., et al. Spatial and temporal heterogeneity in high-grade serous ovarian cancer: a phylogenetic analysis. PLoS Med, 12(2), 2015, e1001789.
4. 4 Yamamoto, S., Maki, D.D., Korn, R.L., et al. Radiogenomic analysis of breast cancer using MRI: a preliminary study to define the landscape. AJR Am J Roentgenol 199:3 (2012), 654–663.
5. 5 Wibmer, A., Hricak, H., Gondo, T., et al. Haralick texture analysis of prostate MRI: utility for differentiating non-cancerous prostate from prostate cancer and differentiating prostate cancers with different Gleason scores. Eur Radiol 25:10 (2015), 2840–2850.
6. 6 Sottoriva, A., Spiteri, I., Piccirillo, S.G., et al. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc Natl Acad Sci U S A 110:10 (2013), 4009–4014.
7. 7 Gerlinger, M., Rowan, A.J., Horswell, S., et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366:10 (2012), 883–892.
8. 8 Grove, O., Berglund, A.E., Schabath, M.B., et al. Quantitative computed tomographic descriptors associate tumor shape complexity and intratumor heterogeneity with prognosis in lung adenocarcinoma. PLoS One, 10(3), 2015, e0118261.
9. 9 Andor, N., Graham, T.A., Jansen, M., et al. Pan-cancer analysis of the extent and consequences of intratumor heterogeneity. Nat Med 22:1 (2016), 105–113.
10. 10 Morris, L.G., Riaz, N., Desrichard, A., et al. Pan-cancer analysis of intratumor heterogeneity as a prognostic determinant of survival. Oncotarget 7:9 (2016), 10051–10063.
11. 11 Gatenby, R.A., Grove, O., Gillies, R.J., Quantitative imaging in cancer evolution and ecology. Radiology 269:1 (2013), 8–15.
12. 12 Gillies, R.J., Kinahan, P.E., Hricak, H., Radiomics: images are more than pictures, they are data. Radiology 278:2 (2016), 563–577.
13. 13 Kumar, V., Gu, Y., Basu, S., et al. Radiomics: the process and the challenges. Magn Reson Imaging 30:9 (2012), 1234–1248.
14. 14 Lambin, P., Rios-Velazquez, E., Leijenaar, R., et al. Radiomics: extracting more information from medical images using advanced feature analysis. Eur J Cancer 48:4 (2012), 441–446.
15. 15 O'Connor, J.P., Rose, C.J., Waterton, J.C., et al. Imaging intratumor heterogeneity: role in therapy response, resistance, and clinical outcome. Clin Cancer Res 21:2 (2015), 249–257.
16. 16 Colen, R., Foster, I., Gatenby, R., et al. NCI Workshop Report: clinical and computational requirements for correlating imaging phenotypes with genomics signatures. Translat Oncol 7:5 (2014), 556–569.
17. 17 MeSH browser. Genomics, 2016, National Library of Medicine (US), Bethesda, MD Available at: http://www.ncbi.nlm.nih.gov/mesh/68023281 [Accessed 21 July 2016].
18. 18 MeSH browser. Proteomics, 2016, National Library of Medicine (US), Bethesda, MD Available from: http://www.ncbi.nlm.nih.gov/mesh/?term=proteomics [Accessed 21 July 2016].
19. 19 Ahmed, A., Gibbs, P., Pickles, M., et al. Texture analysis in assessment and prediction of chemotherapy response in breast cancer. J Magn Reson Imaging 38:1 (2013), 89–101.
20. 20 Rose, C.J., Mills, S.J., O'Connor, J.P., et al. Quantifying spatial heterogeneity in dynamic contrast-enhanced MRI parameter maps. Magn Reson Med 62:2 (2009), 488–499.
21. 21 Chen, C.K., Wu, H.T., Chiou, H.J., et al. Differentiating benign and malignant soft tissue masses by magnetic resonance imaging: role of tissue component analysis. J Chin Med Assoc 72:4 (2009), 194–201.
22. 22 Fehr, D., Veeraraghavan, H., Wibmer, A., et al. Automatic classification of prostate cancer Gleason scores from multiparametric magnetic resonance images. Proc Natl Acad Sci U S A 112:46 (2015), E6265–E6273.
23. 23 Aerts, H.J., Velazquez, E.R., Leijenaar, R.T., et al. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Comm, 5, 2014, 4006.
24. 24 Zhou, M., Hall, L., Goldgof, D., et al. Radiologically defined ecological dynamics and clinical outcomes in glioblastoma multiforme: preliminary results. Translat Oncol 7:1 (2014), 5–13.
25. 25 Nair, V.S., Gevaert, O., Davidzon, G., et al. Prognostic PET 18F-FDG uptake imaging features are associated with major oncogenomic alterations in patients with resected non-small cell lung cancer. Cancer Res 72:15 (2012), 3725–3734.
26. 26 Klaeser, B., Wiskirchen, J., Wartenberg, J., et al. PET/CT-guided biopsies of metabolically active bone lesions: applications and clinical impact. Eur J Nucl Med Mol Imaging 37:11 (2010), 2027–2036.
27. 27 Tatli, S., Gerbaudo, V.H., Mamede, M., et al. Abdominal masses sampled at PET/CT-guided percutaneous biopsy: initial experience with registration of prior PET/CT images. Radiology 256:1 (2010), 305–311.
28. 28 Kuo, M.D., Gollub, J., Sirlin, C.B., et al. Radiogenomic analysis to identify imaging phenotypes associated with drug response gene expression programs in hepatocellular carcinoma. J Vasc Interv Radiol 18:7 (2007), 821–831.
29. 29 Teruel, J.R., Heldahl, M.G., Goa, P.E., et al. Dynamic contrast-enhanced MRI texture analysis for pretreatment prediction of clinical and pathological response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. NMR Biomed 27:8 (2014), 887–896.
30. 30 Yachida, S., Jones, S., Bozic, I., et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467:7319 (2010), 1114–1117.
31. 31 Thews, O., Nowak, M., Sauvant, C., et al. Hypoxia-induced extracellular acidosis increases p-glycoprotein activity and chemoresistance in tumors in vivo via p38 signaling pathway. Adv Exp Med Biol 701 (2011), 115–122.
32. 32 Thews, O., Dillenburg, W., Rosch, F., et al. PET imaging of the impact of extracellular pH and MAP kinases on the p-glycoprotein (Pgp) activity. Adv Exp Med Biol 765 (2013), 279–286.
33. 33 Mehta, S., Shelling, A., Muthukaruppan, A., et al. Predictive and prognostic molecular markers for cancer medicine. Ther Adv Med Oncol 2:2 (2010), 125–148.
34. 34 Hayes, D.F., Biomarker validation and testing. Mol Oncol 9:5 (2015), 960–966.
35. 35 Bai, H.X., Lee, A.M., Yang, L., et al. Imaging genomics in cancer research: limitations and promises. Br J Radiol, 89(1061), 2016, 20151030.
36. 36 Chalkidou, A., O'Doherty, M.J., Marsden, P.K., False discovery rates in PET and CT studies with texture features: a systematic review. PLoS One, 10(5), 2015, e0124165.
37. 37 O'Connor, J.P., Rose, C.J., Jackson, A., et al. DCE-MRI biomarkers of tumour heterogeneity predict CRC liver metastasis shrinkage following bevacizumab and FOLFOX-6. Br J Cancer 105:1 (2011), 139–145.
38. 38 Yap, T.A., Gerlinger, M., Futreal, P.A., et al. Intratumor heterogeneity: seeing the wood for the trees. Sci Translat Med, 4(127), 2012, 127ps10.
39. 39 Ng, C.K., Schultheis, A.M., Bidard, F.C., et al. Breast cancer genomics from microarrays to massively parallel sequencing: paradigms and new insights. J Natl Cancer Inst, 107(5), 2015.
40. 40 Chalmers, I., Glasziou, P., Avoidable waste in the production and reporting of research evidence. Obstet Gynecol 114:6 (2009), 1341–1345.
41. 41 Begley, C.G., Ellis, L.M., Drug development: raise standards for preclinical cancer research. Nature 483:7391 (2012), 531–533.
42. 42 McNutt, M., Journals unite for reproducibility. Science (New York, NY), 346(6210), 2014, 679.
43. 43 Simera, I., Moher, D., Hirst, A., et al. Transparent and accurate reporting increases reliability, utility, and impact of your research: reporting guidelines and the EQUATOR Network. BMC Med, 8, 2010, 24.
44. 44 Wray, N.R., Yang, J., Hayes, B.J., et al. Pitfalls of predicting complex traits from SNPs. Nat Rev Genet 14:7 (2013), 507–515.
45. 45 The future of cancer genomics. Nat Med, 21(2), 2015, 99.
46. 46 Clark, K., Vendt, B., Smith, K., et al. The Cancer Imaging Archive (TCIA): maintaining and operating a public information repository. J Digit Imaging 26:6 (2013), 1045–1057.
47. 47 Rios Velazquez, E., Aerts, H.J., Gu, Y., et al. A semiautomatic CT-based ensemble segmentation of lung tumors: comparison with oncologists' delineations and with the surgical specimen. Radiother Oncol 105:2 (2012), 167–173.
48. 48 van Dam, I.E., van Sornsen de Koste, J.R., Hanna, G.G., et al. Improving target delineation on 4-dimensional CT scans in stage I NSCLC using a deformable registration tool. Radiother Oncol 96:1 (2010), 67–72.
49. 49 Cebulla, J., Kim, E., Rhie, K., et al. Multiscale and multi-modality visualization of angiogenesis in a human breast cancer model. Angiogenesis 17:3 (2014), 695–709.
50. 50 Chandarana, H., Robinson, E., Hajdu, C.H., et al. Microvascular invasion in hepatocellular carcinoma: is it predictable with pretransplant MRI?. AJR Am J Roentgenol 196:5 (2011), 1083–1089.
51. 51 Griffin, N., Addley, H., Sala, E., et al. Vascular invasion in hepatocellular carcinoma: is there a correlation with MRI?. Br J Radiol 85:1014 (2012), 736–744.
52. 52 Segal, E., Sirlin, C.B., Ooi, C., et al. Decoding global gene expression programs in liver cancer by noninvasive imaging. Nat Biotechnol 25:6 (2007), 675–680.
53. 53 Banerjee, S., Wang, D.S., Kim, H.J., et al. A computed tomography radiogenomic biomarker predicts microvascular invasion and clinical outcomes in hepatocellular carcinoma. Hepatology 62:3 (2015), 792–800.
54. 54 Jamshidi, N., Jonasch, E., Zapala, M., et al. The radiogenomic risk score stratifies outcomes in a renal cell cancer phase 2 clinical trial. Eur Radiol 26:8 (2016), 2798–2807.
55. 55 Swanton, C., Intratumor heterogeneity: evolution through space and time. Cancer Res 72:19 (2012), 4875–4882.
56. 56 Jenkinson, M.D., Smith, T.S., Brodbelt, A.R., et al. Apparent diffusion coefficients in oligodendroglial tumors characterised by genotype. J Magn Reson Imaging 26:6 (2007), 1405–1412.